Diffusion Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Brain Cancer Trial of TSC

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that it has successfully completed the first cohort in a Phase I/II clinical trial testing its lead compound trans sodium crocetinate (TSC) in newly diagnosed primary brain cancer patients. All patients in this cohort were treated at the University of Virginia Medical Center in Charlottesville, Virginia. Eleven more institutions have been opened for the second cohort, which has begun enrolling patients. An additional eight institutions will be initiated during the third quarter of 2012, for a total of 20 institutions to enroll 59 patients in the study by the first quarter of 2013.

Back to news